EP2367576B1 - Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé - Google Patents

Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé Download PDF

Info

Publication number
EP2367576B1
EP2367576B1 EP09761017.4A EP09761017A EP2367576B1 EP 2367576 B1 EP2367576 B1 EP 2367576B1 EP 09761017 A EP09761017 A EP 09761017A EP 2367576 B1 EP2367576 B1 EP 2367576B1
Authority
EP
European Patent Office
Prior art keywords
scaffold
anchoring unit
tissue
binding
labelling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP09761017.4A
Other languages
German (de)
English (en)
Other versions
EP2367576A2 (fr
Inventor
David Halter
Ralph Kurt
Emiel Peeters
Roel Penterman
Dirk J. Broer
Rudolf M. J. N. LAMERICHS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips NV filed Critical Koninklijke Philips NV
Priority to EP09761017.4A priority Critical patent/EP2367576B1/fr
Publication of EP2367576A2 publication Critical patent/EP2367576A2/fr
Application granted granted Critical
Publication of EP2367576B1 publication Critical patent/EP2367576B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/18—Materials at least partially X-ray or laser opaque
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/44—Radioisotopes, radionuclides

Definitions

  • the present invention is related to scaffold materials and scaffolds for tissue engineering and organ engineering. More particularly, the present invention is related to the labelling of scaffold materials and scaffolds, which serve as contrast agents for medical imaging means, like CT, MRI, X-Ray, ultrasound, scintigraphy and the like.
  • Tissue engineering is a relatively young discipline which aims at producing, in the laboratory, tissues, or organs, which may then be used to repair, or replace, defective tissues, or organs, of a patient.
  • the said tissues, or organs are being produced with help of a scaffold, this being a three-dimensional matrix which the cells use as basis for their growth, and division, either in vitro or in vivo.
  • a scaffold needs to mimic the in vivo milieu, and enable cells to influence their own microenvironment. In order to do so, it needs to allow cell attachment and migration, deliver and retain cells and biochemical factors, enable diffusion of vital cell nutrients and expressed products, and exert certain mechanical and biological influences to modify the behaviour of the cells.
  • the implanted tissue it is desirable to be able to visually control the actual state of the scaffold. This can be of particular importance for monitoring the continuous bio-degradation of the scaffold and to assess the structural and mechanical properties during this degradation process.
  • the cells growing on the scaffold as well as the scaffolds itself provide little, or even no, contrast compared to the surrounding tissues in clinically relevant imaging modalities such as CT, MRI, X-Ray, scintigraphy and/or Ultrasound imaging, and can therefore hardly be visualized.
  • US2006/0204445 discloses a matrix having a three-dimensional ultrastructure of interconnected fibers and pores to permit cell attachment, and further comprising an image enhancing agent.
  • Said image enhancing agent is an MRI imaging label based on lanthanides and/or transition elements.
  • the matrix comprises biomaterials, such as collagen, elastin, fibrous proteins and/or polysaccharieds, and/or a synthetic polymer, and is for example produced by electrospinning.
  • the image enhancing agents are incorporated within, or on, the scaffold matrix before seeding with cells. When the colonized scaffold forms a tissue layer of cells and is ready for use, the growth, development, and remodeling of the artificial tissue can be monitored using the incorporated agents.
  • Another disadvantage may arise from permanent in-situ release of the respective label, or its matabolic products, once the scaffold, or the tisse or organ, is implanted, namely due to cleavage of the respective bindings, and/or metabolic degradation of the labels, in a physiologic environment, e.g., by effect of ubiquituos esterases and electrolytes.
  • WO 2007/039858 A2 discloses the use of the [3+2] azide-alkyne cycloaddition as biorthogonal reaction in targeted molecular imaging and therapy.
  • a method for the production of scaffold materials and/or scaffolds for tissue and/or organ engineering comprising the addition of at least one anchoring unit for a labelling agent, to at least one scaffold material and/or to at least one scaffold, and the method further comprising the step of binding at least one labelling agent to at least one anchoring unit for a labelling agent, wherein the step of binding at least one labelling agent to at least one anchoring unit is carried out by means of a bio-orthogonal chemical reaction.
  • the said method gives more flexibility to the labelling process, as it allows to postpone the decision which labelling agent is to be used to a later point of time, and decouples it from the scaffold production process.
  • this allows to select the labelling agent in accordance to a potential imaging device.
  • This is particularly useful, as both imaging devices and labelling agents are subject of extensive research and development, in order to achive better images and improve the quality of diagnosis and examination, while reducing costs, side effects in the patient, and environmental problems at the same time.
  • the method according to the invention is thus open to incorporate future labelling agents with better properties as well.
  • anchoring unit for a labelling agent refers to a component of a multiple-component system, in which the components (i.e., at least the anchoring unit for a labelling agent and a labelling agent) may be attached to one another either covalently or non-covalently.
  • the anchoring unit is attached, or incorporated, to the scaffold, whereas the labelling agent is later attached to the anchoring unit either covalently or non-covalently.
  • the method further comprises the step of binding at least one labelling agent to at least one anchoring unit for a labelling agent.
  • the labelling agent does, in most cases, comprise an entity which allows binding to the said anchoring unit.
  • This entity is also called “complememtary binding unit” in the following.
  • the complementary binding unit can either be bound to the labelling agent, or it can form part of the labelling agent.
  • said labelling agent can be selected from the following table, which is not to be understood as limiting the scope of the present invention to the labelling agents mentioned.
  • agents marked with a superscript integer are radionuclides.
  • Table 1 Imaging technology labelling agent Examples X-ray Barium based agents, e.g., barium sulphate based agents iodine based agents Hyperosmolaric (Gastrolux®, Gastrografin®, Peritrast®).
  • spectral CT Gadolinium-complexes non-ionic Iodine based agents Ultravist®, Isovist®, Xenetix® single photon emission computed tomography (Spect) magnetic resonance imaging (MRI)
  • Lanthanaide ions and complexes e.g., Gadolinium-complexes, like Gd-DTP A-BMA PEG-coated iron oxide PEG-Ferron SPIO/Iron oxide nano particles (silicon coated, sup erp aramagnetic) Manganese based agents (Mangan-DPDP) Manganese oxide nano particles perfluorooctyl Bromide bariumsulfate-suspensions Iron Oxide Ferumoxsil 19 Fluorine containing materials, e.g ., perfluorooctyl bromide (PFOB) sonography Gas filled microbubbles positron emission tomography (PET) 11 Carbon, 13 Nitrogen, 15 Oxygen, 18 Fluor
  • the step of binding at least one labelling agent to at least one anchoring unit is carried out by means of a bio-orthogonal chemical reaction.
  • Bio-orthogonal chemical reactions have to meet the following criteria:
  • Binding mechanisms capable of building up such bonds comprise, for example, the so-called “Staudinger reaction” (i.e., the combination of an azide with a phosphine or phosphate to produce an iminophosphorane), the “Staudinger Ligation” (i.e ., formation of an iminophosphorane through nucleophilic addition of the phosphine at the terminal nitrogen atom of the azide and expulsion of nitrogen, see Saxon et al. 2007.), or the so called “click reaction” ( i.e., so called “Strain Promoted [3+2] Azide-Alkyne cycloaddition”, see Agard et al. 2004).
  • Staudinger reaction i.e., the combination of an azide with a phosphine or phosphate to produce an iminophosphorane
  • the “Staudinger Ligation” i.e ., formation of an iminophosphorane through nucleophilic addition of
  • binding mechanisms and binding agents capable of carrying out such mechanism, are for example disclosed in US20080075661A1 , WO2007110811A2 and WO2007039864 . It is particularly important that these binding mechanisms allow for an in vivo-binding (see below) of the labelling agent to the anchoring unit, and thus to the scaffold.
  • bio-orthogonal binding reactions between at least an anchoring unit and at least a labelling agent can be accomplished by biocompatible binding agents.
  • a particularly preferred combination of these binding agents is a pair of complementary oligonucleotides, which bind to one another under appropriate conditions by base pairing (nucleic acid hybridization).
  • nucleic acid refers to, among others, monomers, oligomers and polymers of RNA, DNA, LNA, PNA, Morpholino and other nucleic acid analogues.
  • a peptide nucleic acid (PNA) is an artificially synthesized polymer similar to DNA or RNA which cofeatures backbone composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds.
  • a locked nucleic acid (LNA) is a modified RNA nucleotide in which the ribose moiety is modified with an extra bridge connecting the 2' and 4' carbons.
  • Morpholinos are synthetic analogues of DNA which differ structurally from DNA in that while Morpholinos have standard nucleic acid bases, those bases are bound to morpholine rings instead of deoxyribose rings and linked through phosphorodiamidate groups instead of phosphates.
  • the said oligonucleotides can be single-stranded or, at least in part, double-stranded.
  • the oligonucleotides may have so-called "sticky ends", which are characterized by single strand overhangs.
  • An overhang is a stretch of unpaired nucleotides in the end of a DNA molecule. These unpaired nucleotides can be in either strand, creating either 3' or 5' overhangs. Such sticky ends are shown in Fig. 5 .
  • the said complementary oligonucleotides allow, for example, a controlled binding and cleaving of the labelling agent to the scaffold. These features make the said complementary oligonucleotides particularly useful for in vivo binding, as discussed below.
  • Cleaving can be achieved by using DNA restriction enzymes.
  • DNA restriction enzymes are enzymes that cut double-stranded DNA at specific recognition sequences (known as restriction sites), highly specific cleaving can be obtained by sequence specific design of the respective oligonucleotides. It is preferred, in this context, to select a restriction enzyme, which has
  • Another way of post-imaging release of the labelling agent bound my means of an oligonucleotide is the application of a local temperature increase. This is commonly done by heating the hybridized nucleotides to a temperature of above 85 °C (i.e ., melting temperature).
  • One way to determine the said melting temperature is the so-called Wallace method, which is suitable for oligonucleotides less than 18mers in length. It is being done by counting the frequency of each nucleotide base. The reasoning behind the method is that, because cytosine-guanine pairs form three hydrogen bonds while adenosine and thymine form two hydrogen bonds, the former contribute more to the stability of a double-helix.
  • the locally focused application of heat can for example be accomplished by application of high intensity focused ultrasound (HIFU).
  • HIFU high intensity focused ultrasound
  • the latter is a highly precise medical procedure using high-intensity focused ultrasound to heat (and sometimes destroy) tissue rapidly.
  • Therapeutic ultrasound is a minimally invasive or non-invasive method to deposit acoustic energy into tissue.
  • Conventional applications according to the state of the art include tissue ablation (for tumor treatments, for example) or hyperthermia treatments (low-level heating combined with radiation or chemotherapy).
  • the ultrasound beam can be focused geometrically, for example with a lens or with a spherically curved transducer, or electronically, by adjusting the relative phases of elements in an array of transducers (a "phased array"). By dynamically adjusting the electronic signals to the elements of a phased array, the beam can be steered to different locations, and aberrations due to tissue structures can be corrected.
  • HIFU is in some cases carried out under control of ultrasonography or computerized MRI.
  • oligonucleotides provide the option that a given anchoring unit is being labeled with two or more labelling agents. This allows the simultaneous labelling of a scaffold with two or more different labelling agents (for example to allow sequential, or simultaneous, imaging with two or more different imaging means).
  • an oligonucleotide with 40 residues can for example choose an oligonucleotide with 40 residues (40-mer), together with complementary oligonucleotides being coupled to a labelling agent with 10 residues each (10-mers).
  • an oligonucleotide can comprise a spacer which separates two sequences from one another. Examples are shown in Fig. 6 .
  • spacer refers to a chemical linker, polymer, peptide and the like that spatially separates different sections of a binding agent, like an oligonucleotide.
  • the spacer is selected such that it allows the binding of two or more complementary binding agents in such way that the latter do not interfere with one another.
  • oligonucleotides are linked to a spherical bead incorporated in the scaffold material, as shown in Fig. 13 .
  • the oligonucleotide binding agents are arranged in a three dimensional manner, which faciliates binding of the respective labelling agents.
  • Binding agent 1 can for example act as the complementary binding unit according to the invention, which binds, or forms part of, the labelling agent, and binding agent 2 can be bound to, or act as, the anchoring unit, or vice versa.
  • the anchoring unit can consist essentially of either binding agent 1 or 2. In this case, it is directly bound to the scaffold, and has a free binding moiety for the complementary binding unit which binds, or forms part of, the labelling agent.
  • agent 1 agent 2 complementary oligonucleotide complementary oligonucleotide molecular tag complementary moiety antibody antigen ankyrin complementary moiety lectin sugar, glycoproteins, glycolipds biotin streptavidin, avidin collagen binding proteins collagen ligand tissue specific receptor tissue specific ligand receptor magnetic beads magnetic beads of complementary polarity charged group (e.g., "+”) complementarily charged group ( e.g., "-”) zwitterions complementary zwitterion hydrophilic group hydrophilic group hydrophobic group hydrophobic group bifunctional group complementary bifunctional group
  • zwitterion refers to a molecule has at least one pair consisting of a positively charged group and a negatively charged group. It is crucuial to the invention that in this case a complementary zwitterion exists, so that both zwitterions can act as complementary binding agents.
  • bifunctional group refers to a group which has at least one pair consisting of a hydrophilic and a hydrophobic portion, or subdomain. It is crucial to the invention that in this case a complementary bifunctional group exists, so that both bifunctional groups can act as complementary binding agents.
  • moecular tag refers to molecules which are, for example, being used for the purification of proteins. Examples for these tags are shown, in a non-limiting fashion, in table 5.
  • Table 5 Molecular tag Complementary moeity immobilized metal ions, like Ni-NTA His-tag (Hexahistidine) his-tag (Hexahistidine) immobilized metal ions, like Ni-NTA chitin binding protein (CBP) chitin maltose binding protein (MBP) amylose rProtein L kappa light chain of immunoglobulins (C ⁇ domain) Flag-Tag (DYKDDDDK) antibody Strep-tag biotin Hemagglutinin-tag (HA) immunoglobulin (e.g ., ABIN130391) myc-tag immunoglobulin 9E10 GST (Glutathion-S-Transferase) glutathione V5-tag immunoglobulin
  • bio-orthogonal binding mechanisms discussed above reduce the risk of impairing colonization of the scaffold with cells, or division of cells which have just colonized the scaffold. This is basically due to the fact that the above discussed bio-orthogonal binding mechanisms, or binding agents (like azide groups or oligonucleitoides) are less likely to have detrimental effects on cells than most of the labelling agents discussed above.
  • reaction types for binding a labelling agent to an anchoring unit are shown in the following table, which is not to be understood as being part of the present invention in its entirety.
  • Table 6 Reaction type example cycloaddition Huisgen 1,3-dipolar cycloaddition Diels-Alder reaction nucleophilic substitution small strained rings like epoxy and aziridine compounds carbonyl-chemistry-like formation of urease addition reactions to carbon-carbon double bonds dihydroxylation
  • the polymeric scaffold materials and/or scaffolds are produced by at least one method selected from the group consisting of
  • Electrospinning is a method for generating ultrathin fibers from materials such as polymers, composites, and others. Nanofibers of both solid and hollow interiors (“nanotubes”) can be formed as well.
  • the thin fibers are produced by uniaxial stretching of a viscoelastic jet derived from a polymer solution or melt by applying high voltages. The fibers are deposited on a flat surface and lead to a complex meshwork which afterwards can be shaped.
  • the electrospinning process for making scaffolds is known in the art as described by Van Lieshout et al. (2006).
  • Rapid prototyping refers to methods for the construction of physical objects using solid freeform fabrication, i.e., without a mould. Rapid prototyping takes virtual designs from computer aided design (CAD) or animation modeling software, transforms them into thin, virtual, horizontal cross-sections and then creates each cross-section in physical space, one after the next until the model is finished.
  • Table 7 gives a non-limiting overview of some rapid prototyping methods which can be used in the context of the present invention.
  • Table 7 Prototyping Technologies Base Materials (examples) Selective laser sintering (SLS) thermoplastics, metals powders Fused Deposition Modeling (FDM) thermoplastics, eutectic metals. Stereolithography (SLA), or three dimensional lithography photopolymerizable polymers Electron Beam Melting (EBM) titanium alloys 3D Printing (3DP) various Solid ground curing (SGC) photopolymerizable polymers
  • Knitting is a method well known in the art. In scaffold production, it allows the production of an open structure that is mechanically reliable.
  • An advantage of knitting is the complex geometries that can be produced, e.g., branched prostheses used for aortic arch replacements Among the materials that have been used for knitting are Dacron, but also carbon fibers as well as polymers like polycaprolactone. The knitting process for making scaffolds is as well described by Van Lieshout et al. (2006).
  • Phase separation comprises different approaches, them being immersion precipitation, solid-liquid phase separation, liquid-liquid phase separation, polymerization-induced phase separation and particularly thermally induced phase separation ("TIPS").
  • the lattter is a method that requires the use of a solvent with a low melting point that is easy to sublime. This can for example be done with dioxane as a solvent for polylactic acid.
  • Phase separation is then induced by addition of a small quantity of water, which leads to the formation of a polymer-rich phase and a polymer-poor phase. The mixture is then cooled below the solvent melting point, and vacuum-dried, to sublime the solvent in order to obtain a porous scaffold.
  • the scaffold material is a biodegradeable material.
  • biodegradeable material can be selected from, among others, collagen I, collagen II, collagen III, collagen IV, collagen V, collagen VI, collagen VII, collagen VIII, collagen IX, collagen X, elastin, poly(lactide-co-glycolides) (PLGA), polycarpolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), tissue culture plastic (TCP), poly (propylene fumarate (PPF), poly(ethylene glycol) terephthalate (PEGT), poly(butylene terephthalate), Peptide Hydrogels (e.g., PuraMatrixTM), polysaccharidic materials, particularly chitosan or glycosaminoglycans (GAGs), hyaluronic acid, particularly in combination with cross linking agents (e.g., glutaraldehyde, paraforaldehyde, or water soluble carbodiimide), or mixtures
  • cross linking agents
  • the anchoring unit is added to the reaction mixture prior to polymerization.
  • the anchoring unit is added, e.g., to the monomer mixture prior to polymerization.
  • the anchoring unit is thus added to the said cyclic dimmer.
  • the anchoring unit is attached to the polymer from which the scaffold is formed.
  • the anchoring unit is added, e.g., to the polymer prior to formation of the scaffold, e.g., by electrospinning and/or rapid prototyping. This again yields for an even distribution of the anchoring unit in the later scaffold.
  • the anchoring unit is attached after the forming of the scaffold.
  • the anchoring unit is mainly attached to the surface of the scaffold. This makes sense for in vivo labelling applications (see below), as here the binding of the labelling agent can only take place on the surface of the scaffold.
  • the attachment of the anchoring unit to the scaffold is, in a preferred embodiment, a covalent binding step.
  • the attachment of the anchoring unit to the scaffold is a non-covalent binding step, as for example shown in Fig. 3 .
  • the method according to the invention is characterized in that the labelling agent is bound to the anchoring unit in vivo.
  • in vivo shall refer to a binding process which takes place once the scaffold is implanted in a patient. It can be used interchangeably with the term “in situ”.
  • a labelling agent which is in some cases a potentially allergenic, or even toxic, agent, for a period as short as possible, e.g., only directly before the imaging process.
  • the labelling agent is released again after the imaging experiment.
  • a labelling agent When need for a scaffold check arises, one may then administer a labelling agent to the patient, which, once in the blood flow, binds to the anchoring units, allowing thus a proper imaging of the complete scaffold. After the medical examination, the binding can be cleaved and the labelling agent is released, and will be excreted with the urine, for example.
  • labelling agents like gadolinium (Gd)-based agents, have poor biocompatiblity, and it is not desirable to have these agents in the body for an extended period of time, as Gd could be released from the complexes and lead to health problems if residing too long in the body.
  • methods according to the prior art provide that the labellling agent is added to the scaffold, or the scaffold material, prior to implantation.
  • the in vivo use allows adding even after an extended period of time.
  • the labelling agent can be added, e.g., one year after the scaffold was implanted into the body. This can be advantageous as during this extended time the imaging label can be degraded, or released, if introduced prior to implantation, thus degrading the labelling function over time.
  • a controlled binding and cleaving has several advantages, as it allows the time controlled binding, and removal, of a labelling agent
  • radionuclides as labelling agents (see table 1), which are necessary for some imaging modalities, such as PET, SPECT, scintigraphy or other nuclear medicine tomographic imaging techniques (see table 1)
  • the labelling agent is bound to the anchoring unit in vitro.
  • in vitro shall refer to a binding process which takes place prior to implantation of the scaffold. The advantage of the in vitro binding is that harsher conditions for the chemical coupling reaction can be applied, resulting in a more reliable binding. Furthermore, a greater number of binding reactions is available for the in vitro approach.
  • a scaffold is, in a preferred embodiment, obtainable by a method according to the invention.
  • Said scaffold is, in another preferred embodiment being used for the production of at least one tissue and/or organ selected from the group consisting of
  • tissue and/or organ for the manufacture of a tissue and/or organ is provided, as well as a tissue and/or organ comprising such scaffold.
  • Said tissue and/or organ is preferably selected from at least one of the group consisting of
  • the invention comprises, in another embodiment, a method of labelling a scaffold material and/or a scaffold for tissue and/or organ engineering according to the invention, said method comprising the step of binding at least one labelling agent to the anchoring unit.
  • the at least one labelling agent is bound to the anchoring unit by means of a bio-orthogonal chemical reaction.
  • the method comprises the step of releasing at least one labelling agent from the anchoring unit in vivo.
  • tissue engineering refers to an interdisciplinary field that applies the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function or a whole organ. It comprises the use of a combination of cells, engineering and materials methods, and suitable biochemical and physio-chemical factors, to improve or replace biological functions, particularly tissues and/or organs.
  • tissue engineering requires, in most cases, a scaffold and living cells to colonize the former.
  • Scaffold relates to a three dimensional matrix on which cells are grown. These matrices are often critical, both ex vivo as well as in vivo, to recapitulating the in vivo milieu and allowing cells to influence their own microenvironments. Scaffolds usually serve at least one of the following purposes:
  • scaffolds must meet some specific requirements.
  • a high porosity and an adequate pore size are necessary to facilitate cell seeding and diffusion throughout the whole structure of both cells and nutrients.
  • Biodegradability is often an essential factor in case the scaffolds are supposed to be absorbed by the surrounding tissues over time without the necessity of a surgical removal.
  • the rate at which degradation occurs has to coincide as much as possible with the rate of tissue formation. This means that while cells are fabricating their own natural matrix structure around themselves, the scaffold provides structural integrity within the body, and eventually it will break down leaving the so called neotissue, i.e ., newly formed tissue which will take over the mechanical load.
  • Cells as used for tissue engineering comprise, among others, fibroblasts and/or keratocytes (for skin replacement or repair), chondrocytes (for cartilage replacement or repair), stem cells (large variety of potential tissues to be replaced, or repaired), pluripotent cells (large variety of potential tissues to be replaced, or repaired), cardiac stem cells (for the repair or replacement of cardiac tissue), endothelial stem cells (for the repair or replacement of vascular tissue), valve stem cells (for the repair or replacement of heart valves), and so forth.
  • fibroblasts and/or keratocytes for skin replacement or repair
  • chondrocytes for cartilage replacement or repair
  • stem cells large variety of potential tissues to be replaced, or repaired
  • pluripotent cells large variety of potential tissues to be replaced, or repaired
  • cardiac stem cells for the repair or replacement of cardiac tissue
  • endothelial stem cells for the repair or replacement of vascular tissue
  • valve stem cells for the repair or replacement of heart valves
  • the cells used comprise, extended telomeres, in order to increase their dividing potential and/or lifetime, which is restricted, in non-modified cells, by the so-called Hayflick limit.
  • the cells used are autologous cells, i.e ., cells which are genetically compatible with the recipient of the tissue or organ produced therewith. This is basically the case if the cells are derived from the same subject to which the cells are applied ( i.e ., donor and recipient are the same person), or in case donor and recipient are close relatives.
  • complementary nucleic acid and “complementary oligonucleotide” refer to nucleic acids, polynucleotides and/or oligonucleotides which have base sequence comprising any of the bases cytosine (C), guanine (G), adenine (A), thymine (T) and uracil (U), or to Hypoxanthine, Xanthine, 7-Methylguanine, 5,6-Dihydrouracil, 5-Methylcytosine, isoguanine and isocytosine, that is capable of hybridizing to another nucleic acid, polynucleotide and/or oligonucleotide according to the Watson-Crick base pairing mechanism.
  • antibody and “monoclonal antibody” refer to immunoglobulin molecules exhibiting a binding affinity towards a given antigen, and which are either produced by immunized mammals, or by recombinant microorganisms.
  • Lectins are sugar-binding proteins which are highly specific for their sugar moieties. They typically play a role in biological recognition phenomena involving cells and proteins. For example, some bacteria use lectins to attach themselves to the cells of the host organism during infection.
  • Ankyrin repeats are derived from natural ankyrin repeat proteins which are used in nature as versatile binding proteins with diverse functions such as cell signalling, kinase inhibition or receptor binding just to name a few. These ankyrin repeats are for example described in EP1332209 .
  • Streptavidin is a 53 Kd protein purified from the bacterium Streptomyces avidinii, which exhibits strong affinity for the vitamin biotin; the dissociation constant (Kd) of the biotin-streptavidin complex is on the order of ⁇ 10-15 mol/L. Avidin is a similar protein which has as well a strong affinity to biotin.
  • labelling agent refers to an agent, i.e., a molecule, which can be made visible by means of an imaging apparatus, like an X-ray, a computer tomograph (CT, particularly spectral CT, a Magnetic Resonance Imager (MRI), a sonograph, a positron emission tomograph (PET) and/or a scintigraph (see table 1).
  • CT computer tomograph
  • MRI Magnetic Resonance Imager
  • PET positron emission tomograph
  • scintigraph see table 1
  • the visualization is particularly useful when an embodiment labelled with said labelling agent is implanted into the human body. In this case, on would speak of in situ visualization, or in vivo visualization. Frequently, the said labelling agents are also termed "contrasting agents”.
  • Fig. 1 shows, in an exemplary fashion, a scaffold 1 for an artificial heart valve.
  • the scaffold is made by electrospinning of a polymer, a mixture of different non-modified or modified polymers, or a mix of a polymer and other materials/entities. This leads to a material comprising long fibers 2, to which anchoring units 3, 4 according to the invention are attached.
  • Fig. 2a shows some elements of the invention, namely monomers 5, a polymer 6, an anchoring unit 7 covalently bound to a monomer 5, a labelling agent 8, and another anchoring unit 9 not covalently bound to a monomer.
  • the labelling agent 8 can be bound to, or form part of, an entity which allows binding to the anchoring unit 7 or 9. This entity is also called “complementary binding unit”.
  • the anchoring unit 9 is bound to a particle which can be incorporated, non-covalently, in a scaffold during the electrospinning process.
  • Fig. 2b shows a preferred embodiment of the invention in which the attachment of the anchoring units takes place prior to polymerization of the monomers.
  • the polymers thus produced can then undergo electrospinning. Later on, labelling agents can be bound to the anchoring units, particularly in vivo.
  • Labelling agents to be used for MRI can be 19 F-containing materials, chemical shift agents to shift proton signal of protons in the scaffold or lanthanide ions, e.g., gadolinium Gd-containing complexes. Other agents that can be used for MRI are of course also possible. Furthermore, labelling agents to be used for other imaging modalities (CT, X-ray) can be used as well. Gd-complexes can also be used for spectral CT, which is more sensitive than conventional CT (see table 1).
  • Fig. 3 shows a process in which anchoring units not covalently bound to a monomer are mixed with polymerized scaffold matter, and do then undergo a co-electrospinning, in such way that the anchoring agents are incorporated in the fibers thus produced. Later on, labelling agents can be bound to the anchoring units, particularly in vivo.
  • Fig. 4a shows, as an example for the bio-orthogonal binding of a labelling agent to an anchoring unit, the so-called Staudinger ligation.
  • the monomer comprises a chemical modification which acts as an anchoring unit according to the invention, namely an azide (N 3 -group) 10, which can click to a phosphine group 11 which carries the labelling agent.
  • the monomer can also be coupled to the phosphine group (11), which does in this case act as the anchoring unit according to the invention, and then the labelling agent is attached, by its azide group (10), to the anchoring unit.
  • the anchoring unit and the complementary binding unit of the labelling agent can as well be complementary strands of oligonucleotides, which can form stable non-covalent bonds in vivo and are able to target the label specifically to the site where it is needed.
  • Fig. 4b shows, as another example for the bio-orthogonal binding of a labelling agent to an anchoring unit, the so-called click-reaction, in which the modified monomer clicks to a strain-stressed alkyne.
  • Fig. 5a shows a single-stranded oligonucleotide bound to an anchoring unit, and a complementary single-stranded oligonucleotide bound to a labelling agent. Both can hybridize with each other, particularly in an in vivo situation, thus binding a labelling agent to a scaffold just in time (see above). Under certain circumstances, the hybridization can later be cleaved again, e.g., by application of locally focused heat or by restriction enzymes.
  • Fig. 5b shows two double-stranded oligonucleotides with sticky ends, which can be used as binding agents according to the invention.
  • the overhangs are complementary to one another, thus allowing a binding by hybridization.
  • One of the shown oligonucleotides may be coupled to an anchoring unit, or even form part of it.
  • the said complementary oligonucleotides allow, for example, a controlled binding and cleaving of the labelling agent to the scaffold.
  • cleaving can take place by application of heat, or a restriction enzyme. In the latter case, it is preferred that the cleaving site of the restriction enzyme corresponds to the sequences of the sticky ends.
  • Fig. 6 shows different examples of other nucleotides serving as binding agents according to tzhe invention.
  • Fig 6a an oligonucleotide with 40 residues (40-mer), is shown together with two complementary oligonucleotides with 10 residues each (10-mers), each being coupled to a labelling agent.
  • the oligonucleotide has two sections being complementary to two oligonucleotides which carry a labelling agent each, the two sections being separated from one another by an oligomer with a length of n residues.
  • the oligonucleotide has three sections being complementary to three oligonucleotides which carry a labelling agent each, thus allowing the use of three different labelling agents
  • an oligonucleotide which comprises a spacer which seperates two sequences from one another, thus allowing for a spatially separated hybridization of two complementary oligonucleotides which carry a labelling agent each.
  • Figs. 7 - 9 show the steps of labelling a scaffold with click chemistry comprising a covalently bound anchoring unit. These Figures are discussed in connection with example 1.
  • Figs. 10 - 12 show the steps of labelling a scaffold by means of Gd-labelled oligonucleotides. These Figures are discussed in connection with example 3.
  • Fig. 13 shows several oligonucleotide binding agents linked to a spherical bead incorporated into the scaffold material.
  • the oligonucleotide binding agents are arranged in a three dimensional manner ( e.g., in a tetraedric shape, while, in Fig. 13 , this is projected in a two dimensional manner).
  • the spherical bead is, in this example, a Gold particle, as described in example 3.
  • the three dimensional arrangement has several advantages. First, any steric interactions between the different labelling agents which bind to the oligonucleotide binding agents are reduced to a minimum.
  • the arrangement provides the option to use different oligonucleotide binding agents (i.e ., which differ from one another by their sequences, as shown in Fig. 13 ), in order to allow the use of different labelling agents which in turn might be useful for different imaging devices.
  • Another advantage is that such arrangement improves the binding properties in case the spherical bead is incorporated in a scaffold material. In such way the likelihood is increased that at least one binding agent peeks put of the scaffold material and is thus available for binding to a labelling agent.
  • the different oligonucleotides may have the same sequence preferably.
  • Example 1 Labelling of a scaffold with click chemistry comprising a covalently bound anchoring unit.
  • a copolymer of ⁇ -caprolactone and ⁇ -bromo- ⁇ -caprolactone (or a pure ⁇ -bromo- ⁇ -caprolactone) is being produced, which serves as a polymer for formation of the scaffold.
  • This process is described in examples 1.1. - 1.3.
  • the Br-groups of the copolymer are being substituted by azide (N 3 )-groups, the latter being the anchoring units of the present invention.
  • the copolymer can undergo a scaffold formation process, e.g., by electrospinning, prior or after the substitution process. Labelling agents are being bound to the anchoring units by means of a staudinger reaction.
  • ⁇ -bromocyclohexanone is synthesized according to the following procedure: To a stirred mixture of 30 g (0.306 mol) of cyclohexanone and 200 mL of distilled water, 49 g (0.306 mol) of bromine is added dropwise over a period of 5 h, during which the temperature is maintained between 25 and 30 °C by external cooling.
  • Random ring opening polymerization is carried out at 25 °C in toluene.
  • 15 mL of toluene, 0.628 g (3.25 mol) of ⁇ BrCL in toluene, 5.507 g (48.31 mmol) of ⁇ CL, and 0.307 g of aluminum isopropoxide (Al(O-i-Pr) 3 , 1.5 mmol) in toluene are successively added through a rubber septum with a syringe. After polymerization for 3 h, an excess of 1 N HCl is added, and the is recovered by precipitation in cold methanol. See Fig. 7b for a reaction scheme.
  • the copolymer thus produced is immersed in a saturated solution of sodium azide in 2,5-dimethylfurane (DMF) for 24 h at room temperature.
  • the substrates are then rinsed with DMF, sonicated 3 min in ethanol and 3 min in water, and dried in a stream of air.
  • This process leads to a substitution of Br-groups by azide (N 3 )-groups, the latter being the anchoring units of the present invention. See Fig. 8 for a reaction scheme.
  • a coumarin dye is being used as an exemplary labelling agent.
  • a click reaction between the azide groups of the copolymer and the propyne groups of a coumarin 343 derivative (10-oxo-2,3,5,6-tetrahydro-1H,4H,10H-11-oxa-3aaza-benzo[de]anthracene-9-carboxylic acid prop-2-ynyl ester) is carried out by immersing the azide-functionalized substrate for 24 h in a solution of the coumarin 343 derived (5 mg, 0.015 mmol) dissolved in 10 ml ethanol at room temperature.
  • the said reaction has a particular advatage that it can be carried out in vivo.
  • An oligonucleotide as shown in Fig. 5 is labelled at its 5'-end with 18 F acccording to the method of Kuhnast 2003.
  • 18 F is preferably used in positron emission tomography (PET) and scintigraphy (see table 1).
  • PET positron emission tomography
  • scintigraphy see table 1.
  • a complementary oligonucleotide is anchored to a scaffold material by means according to the art, thus serving as an anchoring unit according to the invention.
  • Methods to bind an oligonucleotide to a silicate surface or to a polymer surface are for example known from the literature related to the manufacture of biochips.
  • Au (Gold) particles can be prepared as described in literature (Grabar et al. (1995)). These particles are easily modified with oligonucleotides, which are functionalized with alkane thiols at one of their termini, e.g., the 5'terminus.
  • DOTA-NHS-ester 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxy-succinimide ester)
  • the mixture is then agitated at room temperature in order to carry out a subsitution reaction.
  • the product is dialyzed against pure H 2 O (cut-off of 6-8 kDa). Then, 1 ⁇ mol GdCl 3 ⁇ 6H 2 O (stock solution of 20 mg/ml) is added. The pH is kept constant between 5.0 and 5.5 (by adding IN HCl or IN NaOH) over night. Then, 1 ⁇ mol EDTA is added in order to chelate excess Gd 3+ . After stirring for 30 min, the milky solution can be purified with a Sephadex G-25 column to remove the EDTA-Gd 3+ and other unreacted low molecular weight compound from the DNA-DOTA-Gd complex. DOTA-NHS-ester is commercially available, e.g., from Macrocyclics, Dallas, Texas, or CheMatech, Dijon, France).
  • a Gd-based labelling agent comprising an oligonucleotide as a complementary binding agent is obtained. See Fig. 11 for an illustration of said process.
  • polycaprolactone (PCL, 80 000 kD molecular weight) is used in a solution (8-20 % w/w PCL in a chloroform:methanol mixture of 5:1 to 7:1 mixing ratio).
  • the colloidal gold coated with DNA-single-strands from step 1 is mixed in an amount of 0.01%). Electrospinning is then performed to build a network of fibers that can be shaped later (this process is described well in literature, e.g., in Van Lieshout et al. (2006) and many others.
  • the DNA-single-strands modified with the Gd-complex are added to the complementary DNA-strands built into the scaffold by means of the Gold particles.
  • Said binding can take place in vitro or in vivo, as described above. See Fig. 12 for an illustration of said binding process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (12)

  1. Procédé de production de matériaux d'ossature polymères et/ou d'ossatures pour la production de tissus et/ou d'organes, ledit procédé comprenant l'addition d'au moins une unité d'ancrage pour un agent de marquage, à au moins un matériau d'ossature et/ou à au moins une ossature et le procédé comprenant en outre l'étape de liaison d'au moins un agent de marquage à au moins une unité d'ancrage pour un agent de marquage, dans lequel l'étape de liaison d'au moins un agent de marquage à au moins une unité d'ancrage est effectuée au moyen d'une réaction chimique bio-orthogonale.
  2. Procédé selon la revendication 1, dans lequel les matériaux d'ossature polymères et/ou les ossatures sont produits par au moins un procédé choisi dans le groupe constitué des suivants :
    a) électrofilage,
    b) prototypage rapide,
    c) tricotage et/ou
    d) séparation de phases.
  3. Procédé selon la revendication 1, dans lequel le matériau d'ossature est un matériau biodégradable et l'unité d'ancrage est agitée au mélange réactionnel avant la polymérisation, dans lequel l'unité d'ancrage est fixée au polymère à partir duquel l'ossature est formée.
  4. Procédé selon la revendication 1, caractérisé en ce que l'unité d'ancrage est fixée après la formation de l'ossature, dans lequel la fixation de l'unité d'ancrage est une étape de liaison covalente.
  5. Procédé selon la revendication 1, caractérisé en ce que la fixation de l'unité d'ancrage est une étape de liaison non covalente.
  6. Procédé selon la revendication 1, caractérisé en ce que l'agent de marquage est lié à l'unité d'ancrage in vivo.
  7. Matériau d'ossature et/ou ossature susceptible(s) d'être obtenu(s) par un procédé selon l'une quelconque des revendications 1 à 6.
  8. Ossature selon la revendication 7, qui est utilisée pour la production d'au moins un tissu et/ou un organe choisi(s) dans le groupe constitué des suivants :
    a) valvules cardiaques artificielles,
    b) greffes vasculaires,
    c) peau,
    d) tissu nerveux,
    e) organes,
    f) vessie,
    g) vaisseaux sanguins,
    h) tissu cartilagineux et/ou
    i) tissu osseux.
  9. Utilisation d'une ossature selon la revendication 7 pour la fabrication d'un tissu et/ou d'un organe.
  10. Tissu et/ou organe comprenant une ossature selon la revendication 7.
  11. Tissu et/ou organe selon la revendication 10, caractérisé(s) en ce que ledit tissu et/ou ledit organe est ou sont choisis parmi au moins l'un du groupe constitué des suivants :
    a) valvules cardiaques artificielles,
    b) greffes vasculaires,
    c) peau,
    d) tissu nerveux,
    e) organes,
    f) vessie,
    g) vaisseaux sanguins,
    h) tissu cartilagineux et/ou
    i) tissu osseux.
  12. Procédé de marquage d'un matériau d'ossature et/ou d'une ossature pour la production de tissus et ou d'organes selon la revendication 7, ledit procédé comprenant l'étape de liaison d'au moins un agent de marquage à l'unité d'ancrage, dans lequel au moins un agent de marquage est lié à l'unité d'ancrage au moyen d'une réaction chimique bio-orthogonale, dans lequel au moins un agent de marquage est lié à l'unité d'ancrage in vivo et ledit procédé comprenant l'étape de libération d'au moins un agent de marquage de l'unité d'ancrage in vivo.
EP09761017.4A 2008-11-24 2009-11-19 Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé Not-in-force EP2367576B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09761017.4A EP2367576B1 (fr) 2008-11-24 2009-11-19 Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169783 2008-11-24
EP09761017.4A EP2367576B1 (fr) 2008-11-24 2009-11-19 Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé
PCT/IB2009/055168 WO2010058361A2 (fr) 2008-11-24 2009-11-19 Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé

Publications (2)

Publication Number Publication Date
EP2367576A2 EP2367576A2 (fr) 2011-09-28
EP2367576B1 true EP2367576B1 (fr) 2019-02-20

Family

ID=42122926

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09761017.4A Not-in-force EP2367576B1 (fr) 2008-11-24 2009-11-19 Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé

Country Status (4)

Country Link
US (1) US20120190793A1 (fr)
EP (1) EP2367576B1 (fr)
CN (1) CN102223905A (fr)
WO (1) WO2010058361A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468305B1 (fr) * 2010-12-03 2016-06-15 Xeltis B.V. Utilisation d'un polymère fluoré en tant qu'agent de contraste dans une imagerie à résonnance magnétique (IRM) 19F à l'état solide, support comprenant ce polymère et utilisation associée
US10501575B2 (en) * 2015-05-26 2019-12-10 The Board Of Regents Of The University Of Texas System Biomimetic fluoroscopic films
WO2017019422A1 (fr) * 2015-07-24 2017-02-02 Wake Forest University Health Services Échafaudages vasculaires à base de coulée et leurs procédés de fabrication
US10733911B2 (en) 2015-10-14 2020-08-04 Humanetics Innovative Solutions, Inc. Three-dimensional ribs and method of three-dimensional printing of ribs for crash test dummy
US10395561B2 (en) 2015-12-07 2019-08-27 Humanetics Innovative Solutions, Inc. Three-dimensionally printed internal organs for crash test dummy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060204445A1 (en) * 2005-03-11 2006-09-14 Anthony Atala Cell scaffold matrices with image contrast agents
US20070014729A1 (en) * 2005-06-09 2007-01-18 The Hospital For Sick Children Tissue engineered scaffolds and mehtods of preparation thereof
EP1986700A2 (fr) * 2005-10-04 2008-11-05 Koninklijke Philips Electronics N.V. Uilization de la reaction de staudinger en imagerie et en therapie et kit pour l'imagerie et la therapie
WO2007039858A2 (fr) * 2005-10-04 2007-04-12 Koninklijke Philips Electronics N.V. Imagerie et/ou therapie ciblees faisant intervenir la cycloaddition [3+2] azide-alcyne

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2010058361A3 (fr) 2010-07-15
US20120190793A1 (en) 2012-07-26
WO2010058361A2 (fr) 2010-05-27
EP2367576A2 (fr) 2011-09-28
CN102223905A (zh) 2011-10-19

Similar Documents

Publication Publication Date Title
El-Husseiny et al. Smart/stimuli-responsive hydrogels: State-of-the-art platforms for bone tissue engineering
Mishra et al. Bioinspired nanocomposites: applications in disease diagnosis and treatment
Woodruff et al. The return of a forgotten polymer—Polycaprolactone in the 21st century
Lee et al. Alginate: properties and biomedical applications
Arora et al. Nano‐regenerative medicine towards clinical outcome of stem cell and tissue engineering in humans
Koutsopoulos Molecular fabrications of smart nanobiomaterials and applications in personalized medicine
CN101301491B (zh) 多醛基海藻酸钠交联聚磷酸钙/壳聚糖的复合支架及其制备与应用
EP2367576B1 (fr) Procédé de fabrication d'échafaudages moléculaires pour l'ingénierie tissulaire utilisant une unité d'ancrage, et échafaudage moléculaire fabriqué par ce procédé
AA Scaffolds in tissue engineering
Ordikhani et al. Targeted nanomedicines for the treatment of bone disease and regeneration
Martins et al. 3D printing: Prospects and challenges
Bouguéon et al. Micro-and nano-formulations for bioprinting and additive manufacturing
Deepika et al. Applications of nanoscaffolds in tissue engineering
Bag et al. Recent advancement of nanostructured materials: a compatible therapy of tissue engineering and drug delivery system
Lukin et al. Nanomaterial-based drug delivery of immunomodulatory factors for bone and cartilage tissue engineering
Khan et al. Polymer-based bionanomaterials for biomedical applications
Maheshwari et al. Nanotechnology in tissue engineering
Kiparissides et al. Nanotechnology advances in diagnostics, drug delivery, and regenerative medicine
Liang et al. An update on the advances in the field of nanostructured drug delivery systems for a variety of orthopedic applications
Liao et al. Propelling Minimally Invasive Tissue Regeneration with Next‐Era Injectable Pre‐Formed Scaffolds
Ahmad et al. Nanomedicine and tissue engineering
Beilharz et al. Advances in Injectable Polymeric Biomaterials and Their Contemporary Medical Practices
Omidi et al. Impacts of biodegradable polymers: Towards biomedical applications
Armentano et al. Multifunctional nanostructured biopolymeric materials for therapeutic applications
Formoso et al. Progress of nanotechnology in the development of medicines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110624

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KONINKLIJKE PHILIPS N.V.

17Q First examination report despatched

Effective date: 20150522

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTG Intention to grant announced

Effective date: 20180627

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180827

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LAMERICHS, RUDOLF M. J. N.

Inventor name: PEETERS, EMIEL

Inventor name: HALTER, DAVID

Inventor name: BROER, DIRK J.

Inventor name: KURT, RALPH

Inventor name: PENTERMAN, ROEL

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009057064

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1097338

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190620

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190520

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190520

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190521

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190620

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1097338

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009057064

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

26N No opposition filed

Effective date: 20191121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20191126

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191230

Year of fee payment: 11

Ref country code: GB

Payment date: 20191128

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191119

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602009057064

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20201119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20091119

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210601

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190220